Cybin Raises C$45 Million: The Largest Go Public Capital Raise in the Canadian Psychedelic Sector
October 22, 2020
Ryan Allway October 22nd, 2020 Psychedelics, Top Story The COMPASS Pathways Inc. (NASDAQ: CMPS) initial public offering on the NASDAQ has reinvigorated the psychedelics industry over the past couple of weeks. While COMPASS Pathways Inc. is certainly one of the largest companies in the space, there are a handful... Read more
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
October 20, 2020
Ryan Allway October 20th, 2020 Psychedelics Expanding research and development of naturally-derived psilocybin for future FDA IND-enabling and clinical studies October 20, 2020 07:00 ET | Source: Revive Therapeutics Ltd. TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences... Read more
Cybin and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO
October 19, 2020
Ryan Allway October 19th, 2020 Psychedelics CLARMIN EXPLORATIONS INC. (TSXV: CX.V) and CYBIN CORP. (“CYBIN” or the “Company”), a life sciences company focused on psychedelic pharmaceutical therapies, announce the closing of a private placement offering by the Company (the “Offering) of an aggregate of 60,000,000 subscription receipts (the “Subscription... Read more
Ryan Allway October 19th, 2020 Psychedelics Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“ Pharmather ” or the “ Company ”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license... Read more
Havn Life Applies for License to Produce and Sell Psilocybin
October 19, 2020
Ryan Allway October 19th, 2020 Psychedelics Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has submitted an application to Health Canada... Read more
Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
October 19, 2020
Ryan Allway October 19th, 2020 Psychedelics A peer-reviewed study published today in the research journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is remarkably cost-effective when compared to currently available treatments for posttraumatic stress disorder (PTSD). It is estimated that a public healthcare payer or private insurer making MDMA-assisted psychotherapy available to 1,000 patients with PTSD... Read more
Field Trip Health Commences Trading on the CSE
October 12, 2020
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Newscope Capital Announces Listing on the CSE
October 12, 2020
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Havn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors
October 9, 2020
Ryan Allway October 9th, 2020 Psychedelics Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the “Company” or “Havn Life”) is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the “Board”). Mr. Neufeld brings a wealth of knowledge and experience in... Read more
Ryan Allway October 9th, 2020 Psychedelics Tryp Therapeutics Inc. (“Tryp” or the “Company“), a pharmaceutical company developing therapeutics specifically targeting diseases with high unmet medical needs announced today the formation of a Scientific Advisory Board (“SAB“) for its Psilocybin For Neuropsychiatry (“PFN™“) program. The PFN™ SAB is a preeminent... Read more
